Mr. Andre Larente reports

MEXICO'S LARGEST OPTICAL RETAILER TO USE DIAGNOS' AI TECHNOLOGY TO DETECT EARLY STAGE BLINDNESS

Diagnos Inc. has signed a contract with Devlyn Grupo, an important optical retailer with over 900 stores in Mexico and Guatemala. Devlyn will be testing the CARA (computer-assisted retina analysis) artificial intelligence technology for diabetic retinopathy screening at select optical retail locations. A rollout to more stores may happen in early 2021, if testing is conclusive.

"I am pleased to announce our collaboration with Diagnos. Devlyn, which has a long-lasting tradition in optical and clinical eye care, offers the very best of vision care, while adhering to strict safety protocols during the pandemic. Digitalization, telemedicine and accurate clinical eye tests from Diagnos's CARA AI platform supports our mission," said Melanie Devlyn, chief executive officer of Devlyn.

Andre Larente, president of Diagnos, commented: "Diagnos is proud to join Devlyn's well-known reputation of optical and clinical eye care services. We're determined to strongly enhance Devlyn's great work contribution in the world of vision health with our advanced and flexible real-time AI solution for the prevention and avoidance of vision-threatening diseases."

Diagnos is also announcing a correction to its press release dated Sept. 28, 2020. The press release mentions that Vincent Duhamel is vice-chairman of Fiera Capital's board of directors. However, Mr. Duhamel ceased to be vice-chairman of Fiera Capital's board of directors on June 30, 2020. This correction does not change any other information reported in the press release.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation with a mission of early detection of critical health issues through the use of its artificial intelligence tool, CARA. CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA's artificial intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is: accessible securely over the Internet; compatible with all recognized image formats and brands of fundus cameras; and EMR (electronic medical record) compatible. CARA is a cost-effective tool for screening large numbers of patients in real time. CARA complies with local regulations; is U.S. Food and Drug Administration cleared for commercialization in the United States; is Health Canada licensed for commercialization in Canada; and is CE marking compliant in Europe.

We seek Safe Harbor.